Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.62 |
| ▸ | MEN1 | O00255 | 8/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 5/20 | 0.58 |
| ▸ | RAB9A | P51151 | 5/20 | 0.58 |
| ▸ | POLB | P06746 | 5/20 | 0.58 |
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.58 |
| ▸ | RELA | Q04206 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | NSD2 | O96028 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1902177 | 1.00 | MAPT (0.62) | MAPTMEN1KMT2AKDM4ENPSR1 | |
| SCHEMBL27983608 | 0.78 | MAPT (0.82) | MAPTMEN1KMT2AKDM4ENPSR1 | |
| SCHEMBL10476367 | 0.76 | MAPT (0.55) | MAPTMEN1KMT2AKDM4ENPSR1 | |
| SCHEMBL5594048 | 0.76 | MAPT (0.55) | MAPTMEN1KMT2AKDM4ENPSR1 | |
| SCHEMBL10476384 | 0.75 | THRB (0.79) | MAPTMEN1KMT2AKDM4ENPSR1 | |
| SCHEMBL7654815 | 0.75 | KMT2A (0.56) | MAPTMEN1KMT2AKDM4ENPSR1 | |
| SCHEMBL12351215 | 0.74 | MAPT (0.65) | MAPTMEN1KMT2AKDM4ENPSR1 | |
| SCHEMBL10476385 | 0.74 | KMT2A (0.73) | MAPTMEN1KMT2AKDM4ENPSR1 | |
| SCHEMBL10476383 | 0.74 | KMT2A (0.73) | MAPTMEN1KMT2AKDM4ENPSR1 | |
| SCHEMBL26762350 | 0.73 | THRB (0.64) | MAPTMEN1KMT2AKDM4ENPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2322521-B1 | Heteroaryl compounds useful as inhibitors of GSK-3 | VERTEX PHARMA (US) | 2013-09-04 | — | — | EP | disclosed |
| US-7998974-B2 | Fused heterocyclic compounds and their use as sirtuin modulators | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998974-B2 | Fused heterocyclic compounds and their use as sirtuin modulators | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| EP-2322521-A1 | Heteroaryl compounds useful as inhibitors of GSK-3 | Vertex Pharmaceuticals, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| US-20100168084-A1 | Therapeutic compounds and related methods of use | ELIXIR PHARMACEUTICALS, INC. | 2010-07-01 | — | — | US | disclosed |
| US-20100168084-A1 | Therapeutic compounds and related methods of use | ELIXIR PHARMACEUTICALS, INC. | 2010-07-01 | — | — | US | disclosed |
| US-20090143376-A1 | Fused Heterocyclic Compounds and Their Use as Sirtuin Modulators | SITRIS PHARMACEUTICALS, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090143376-A1 | Fused Heterocyclic Compounds and Their Use as Sirtuin Modulators | SITRIS PHARMACEUTICALS, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-20070270420-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED | 2007-11-22 | — | — | US | disclosed |
| US-20070270420-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED | 2007-11-22 | — | — | US | disclosed |
| US-20070270420-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED | 2007-11-22 | — | — | US | disclosed |
| EP-1472245-A2 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3 | Vertex Pharmaceuticals Incorporated (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20040034037-A1 | Heteroaryl compounds useful as inhibitors of GSK-3 | VERTEX PHARMACEUTICALS, INCORPORATED | 2004-02-19 | — | — | US | disclosed |
| WO-2003066629-A2 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143376-A1 | Fused Heterocyclic Compounds and Their Use as Sirtuin Modulators | SIRT1, SIRT3, SIRT2 | MAPT 215/4885MEN1 4100/4885KMT2A 743/4885 |
| US-20070270420-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3 | GSK3B, GSK3A, GSKIP | MAPT 256/4885MEN1 4588/4885KMT2A 2220/4885 |
| US-20100168084-A1 | Therapeutic compounds and related methods of use | EP300, KAT2A, KAT6B | MAPT 1946/4885MEN1 2682/4885KMT2A 422/4885 |
| US-20040034037-A1 | Heteroaryl compounds useful as inhibitors of GSK-3 | GSK3B, GSK3A, GSKIP | MAPT 256/4885MEN1 4588/4885KMT2A 2220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.